PatientsVille.com LogoPatientsVille.com

Papulopustular Rosacea | An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

Papulopustular Rosacea research study

What is the primary objective of this study?

This study is designed to investigate whether topical application of a cromolyn sodium solution is able to decrease the facial redness seen in patients with papulopustular rosacea. Previous work in the lab of Dr. Di Nardo on mice has suggested that cromolyn may be able to have this effect. The study will enroll a total of 10 patients. 5 will randomly be assigned to receive the cromolyn sodium solution, and the other 5 will be randomly assigned to receive the placebo solution. All participants will be instructed to apply their assigned solution twice daily to their face. Patients will return to the clinic 3, 6, and 8 weeks after the distribution of the solutions to measure the efficacy of their assigned solution.

Who is eligible to participate?

Inclusion Criteria: - Subject is male or non-pregnant female, 18 - 80 years of age. - Subjects willing and able to give informed consent. - Subjects willing and able to comply with the requirements of the study. - Subject has the clinical diagnosis of at least mild erythema. - Subject has been on a stable dose for greater than 3 months of medications for treatment of concurrent medical condition (including oral contraceptive pills, vasodilators, adrenergic blocking agents) OR the investigator has determined that the medications are unlikely to affect the patient's rosacea and/or treatment during the study - Subject is in general good health in the opinion of the investigator. Exclusion Criteria: - Subject has a diagnosis of Steroid Rosacea or Pyoderma Faciale (rosacea fulminans) - Subject has a history of Carcinoid, Pheochromocytoma, Serotonin Syndrome or other systemic flushing causes. Subject has used facial topical therapies (OTC drug products or prescription products) for any reason within the prior 28 days - Subject has used systemic corticosteroid or systemic antibiotics (especially doxycycline, minocycline, tetracycline, metronidazole) within the prior 28 days. - Subject has had laser or light-based treatment for rosacea within the prior 3 months. - Subject has had systemic retinoids and retinoid derivatives over the past 6 months - Subject has any history of renal or hepatic insufficiency. - Subject has a known hypersensitivity or allergy to Cromolyn sodium or components of the vehicle. - Subject is pregnant or lactating or planning a pregnancy during the duration of the study - Subject has been treated with another investigational device or drug within 28 days prior to study enrollment or intends to participate in a clinical trial concurrent with this study - Subject has clinically significant findings, medical history or conditions (other than rosacea), which in the opinion of the Investigator may compromise the study, treatment protocol, or safety of the patient or treatment allocation. Subject has a known hypersensitivity or allergy to tape or other adhesive materials

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Papulopustular Rosacea

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Cromolyn Sodium

Drug:Normal Saline

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

CromolynSubjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.

VehicleParticipants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.

Study Status

Unknown status

Start Date: August 2013

Completed Date:

Phase: Phase 1/Phase 2

Type: Interventional

Design:

Primary Outcome: Facial erythema

Secondary Outcome: Matrix Metalloproteinase levels

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: University of California, San Diego

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01933464

Discuss Erythema